Crossmark

Natrium-Glukose-Kotransporter-2-Inhibitoren und Frakturen bei Diabetes mellitus Typ 2

Published Online: 2022-01-21

Published Print: 2022-03

Authors

Pavlicek, Vojtech
License Information

Text and Data Mining valid from 2022-01-21

Version of Record valid from 2022-01-21
More Information

Article History

Accepted: 11 January 2022

First Online: 21 January 2022

Interessenkonflikt

: V. Pavlicek gibt „advisory boards“ für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boehringer Ingelheim und Eli-Lilly an.

Document is current